

EQA round: IHC1/25 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 21.2.2025

Setup: groups - R (manufacturer of kit)

AV = assigned value	N _{tot} = total number of the results	N _{eva} = number of the results assessed
CVE = consensus of the experts	N _{rel} = relative number of the results	N _{suc} = number of successful results
>>> ... expected result		S _{rel} = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(601) A1 expression HER-2/neu		35			35	35	100
Slide		35			35	35	100
(802) Dako HercepTest	CVE >>>	4	11	Negative (0)			
	CVE >>>	2	5,7	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	2	5,7	Negative (0)			
	CVE >>>	2	5,7	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	23	66	Negative (0)			
	CVE >>>	1	2,9	Negative (1+)			
(999) another manufacturer	CVE >>>	1	2,9	Negative (0)			
(602) A2 expression HER-2/neu		37			37	34	92
Slide		37			37	34	92
(802) Dako HercepTest	CVE >>>	1	2,7	Negative (0)			
	CVE >>>	5	14	Negative (1+)			
		1	2,7	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	1	2,7	Negative (0)			
	CVE >>>	3	8,1	Negative (1+)			
		1	2,7	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	13	35	Negative (0)			
	CVE >>>	10	27	Negative (1+)			
		1	2,7	Weak positive (2+)			
(999) another manufacturer	CVE >>>	1	2,7	Negative (1+)			
(603) A3 expression HER-2/neu		37			37	37	100
Slide		37			37	37	100
(802) Dako HercepTest	CVE >>>	7	19	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	14	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	24	65	Strong positive (3+)			
(999) another manufacturer	CVE >>>	1	2,7	Strong positive (3+)			
(606) B1 expression HER-2/neu		34			34	33	97
Slide		34			34	33	97
(802) Dako HercepTest	CVE >>>	1	2,9	Negative (0)			
	CVE >>>	4	12	Negative (1+)			
		1	2,9	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	3	8,8	Negative (0)			
	CVE >>>	2	5,9	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	19	56	Negative (0)			
	CVE >>>	3	8,8	Negative (1+)			
(999) another manufacturer	CVE >>>	1	2,9	Negative (0)			
(607) B2 expression HER-2/neu		37			37	37	100
Slide		37			37	37	100
(802) Dako HercepTest	CVE >>>	6	16	Weak positive (2+)			
	>	1	2,7	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	14	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	20	54	Weak positive (2+)			
	>	4	11	Strong positive (3+)			
(999) another manufacturer	CVE >>>	1	2,7	Weak positive (2+)			
(608) B3 expression HER-2/neu		37			0		
Slide		37			0		
(802) Dako HercepTest	±	1	2,7	Negative (0)			
	±	1	2,7	Negative (1+)			
	±	5	14	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	4	11	Negative (1+)			
	±	1	2,7	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	5	14	Negative (0)			
	±	15	41	Negative (1+)			
	±	4	11	Weak positive (2+)			
(999) another manufacturer	±	1	2,7	Negative (1+)			
(611) C1 expression HER-2/neu		34			34	33	97
Slide		34			34	33	97
(802) Dako HercepTest	CVE >>>	1	2,9	Negative (0)			
	CVE >>>	5	15	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	1	2,9	Negative (0)			
	CVE >>>	2	5,9	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	9	26	Negative (0)			
	CVE >>>	14	41	Negative (1+)			

EQA round: IHC1/25 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 21.2.2025

Setup: groups - R (manufacturer of kit)

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(999) another manufacturer		1	2,9	Weak positive (2+)			
	CVE >>>	1	2,9	Negative (1+)			
(612) C2 expression HER-2/neu		37				0	
Slide		37				0	
(802) Dako HercepTest	±	5	14	Negative (1+)			
	±	2	5,4	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	1	2,7	Negative (0)			
	±	3	8,1	Negative (1+)			
	±	1	2,7	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	2	5,4	Negative (0)			
	±	18	49	Negative (1+)			
	±	4	11	Weak positive (2+)			
(999) another manufacturer	±	1	2,7	Negative (1+)			
(613) C3 expression HER-2/neu		35				0	
Slide		35				0	
(802) Dako HercepTest	±	2	5,7	Negative (1+)			
	±	3	8,6	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	3	8,6	Negative (1+)			
	±	2	5,7	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	4	11	Negative (0)			
	±	9	26	Negative (1+)			
	±	11	31	Weak positive (2+)			
(999) another manufacturer	±	1	2,9	Negative (1+)			
(616) D1 expression HER-2/neu		37			37	37	100
Slide		37			37	37	100
(802) Dako HercepTest	CVE >>>	6	16	Weak positive (2+)			
	CVE >>>	1	2,7	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	14	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	17	46	Weak positive (2+)			
	CVE >>>	7	19	Strong positive (3+)			
(999) another manufacturer	CVE >>>	1	2,7	Weak positive (2+)			
(617) D2 expression HER-2/neu		37			37	37	100
Slide		37			37	37	100
(802) Dako HercepTest	CVE >>>	7	19	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	14	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	22	59	Weak positive (2+)			
	>	2	5,4	Strong positive (3+)			
(999) another manufacturer	CVE >>>	1	2,7	Weak positive (2+)			
(618) D3 expression HER-2/neu		37			37	37	100
Slide		37			37	37	100
(802) Dako HercepTest	CVE >>>	7	19	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	14	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	24	65	Strong positive (3+)			
(999) another manufacturer	CVE >>>	1	2,7	Strong positive (3+)			
(621) E1 expression HER-2/neu		34			34	32	94
Slide		34			34	32	94
(802) Dako HercepTest	CVE >>>	3	8,8	Negative (0)			
	CVE >>>	3	8,8	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	2	5,9	Negative (0)			
	CVE >>>	3	8,8	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	12	35	Negative (0)			
	CVE >>>	8	24	Negative (1+)			
		2	5,9	Weak positive (2+)			
(999) another manufacturer	CVE >>>	1	2,9	Negative (0)			
(622) E2 expression HER-2/neu		37			37	36	97
Slide		37			37	36	97
(802) Dako HercepTest	CVE >>>	1	2,7	Negative (0)			
	CVE >>>	5	14	Negative (1+)			
		1	2,7	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	1	2,7	Negative (0)			
	CVE >>>	4	11	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	11	30	Negative (0)			
	CVE >>>	13	35	Negative (1+)			
(999) another manufacturer	CVE >>>	1	2,7	Negative (1+)			
(623) E3 expression HER-2/neu		25			25	25	100
Slide		25			25	25	100
(802) Dako HercepTest	CVE >>>	5	20	Negative (0)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	3	12	Negative (0)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	17	68	Negative (0)			